Overview

Treatment in Patients With Suspected or Confirmed COVID-19 With Early Moderate or Severe Disease

Status:
Active, not recruiting
Trial end date:
2021-12-10
Target enrollment:
Participant gender:
Summary
This study proposes to evaluate clinical outcomes and viral load in COVID-19 infected patients with early moderate and severe disease admitted to the hospital and randomized to one of three arms. Patients will be randomized to supportive care, OR hydroxychloroquine alone, OR hydroxychloroquine and azithromycin.
Phase:
Phase 3
Details
Lead Sponsor:
LCMC Health
Treatments:
Azithromycin
Hydroxychloroquine